BioWorld: The Daily Biopharmaceutical and Medical Technology …
WEBBioWorld covers the latest developments and trends in biopharmaceutical and medical technology sectors worldwide. Find news, insights and opinions on drugs, devices, diagnostics, biomarkers and more.
BioWorld: The Daily Biopharmaceutical News Source
WEBBioWorld covers the latest developments and trends in biopharmaceutical and medical technology sectors worldwide. Find news, features, interviews and opinions on topics such as drug discovery, clinical trials, regulatory approvals, mergers and acquisitions, and more.
Coronavirus - BioWorld
WEB6 days ago · The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated: Vaccines and therapeutics in development. Diagnostics with U.S. FDA emergency use authorization.
Tessellate Bio draws $8.4M in seed to try alternative synthetic ...
WEBDec 14, 2023 · With an initial €8 million (US$8.4 million) in seed funding in the bank, Tessellate Bio has emerged from stealth to tackle cancers that rely on the less well explored synthetic lethality mechanism of alternative lengthening of telomeres. Cumulus Oncology Ltd. is in the thick of raising a $50 million series A round as its model of sourcing ...
Ideaya nabs Biocytogen’s bispecific ADC program for $406M
WEBAug 1, 2024 · Ideaya Biosciences Inc. bought global rights to Biocytogen Pharmaceuticals Co. Ltd.’s cancer-targeting bispecific antibody-drug conjugate (bsADC) program in a deal reaching up to $406.5 million. Announced July 31, San Francisco-based Ideaya agreed to license-in global rights to Biocytogen’s B7H3/PTK7 bispecific ADC program with topoisomerase-I (TOP1) payload to develop as either a ...
Cancer - BioWorld
WEB2 days ago · Metastatic solid tumors may be curable now. Among the most profound results presented over the weekend at the European Society for Medical Oncology (ESMO) 2024 Congress were the 10-year data from the Checkmate-067 and Keynote-006 trials, the phase III trials that tested Opdivo (nivolumab, Bristol Myers Squibb Co.) and Keytruda (pembrolizumab, Merck & Co. Inc.) as first-line agents in advanced ...
China - BioWorld
WEBSep 10, 2024 · BioWorld covers the latest developments in the biotechnology, pharmaceutical, medical device and medical technology sectors in China. Find out about clinical trials, approvals, deals, innovations and more from China's biotech industry.
Organoids making their US clinical debut with CIDP drug
WEBJul 15, 2022 · Organoids making their US clinical debut with CIDP drug. The use of organoids in preclinical research has reached a tipping point, with U.S. FDA approval of the first drug to enter clinical trials on the basis of efficacy data derived only from these advanced cell models. Cumulus Oncology Ltd. is in …
Characterization of DONQ-52, a multispecific antibody ... - BioWorld
WEBJan 9, 2024 · Patients with celiac disease have gluten-specific CD4+ T cells that recognize gluten via disease-associated human leukocyte antigen (HLA) molecules, specifically HLA-DQ2.5, leading to immune activation and enteropathy.
IGFBP7 SNP tied to the reversal phenotype of amyotrophic lateral ...
WEBDec 7, 2023 · Researchers have defined an amyotrophic lateral sclerosis (ALS) reversal phenotype as having an initial diagnosis of ALS but subsequently showing a progressive and sustained clinical improvement, based on an unusual case they found. It was hypothesized that a genetic influence could play a role here.
Skip to content